In this final episode of our three-podcast series, our faculty return to the disease burden of age-related macular degeneration and discuss shared decision-making and the importance of having an interdisciplinary team, as well as a strong socia
In this episode, our faculty take a deeper dive into their discussion of treatments of neovascular AMD, including anti-VEGF agents and some of the newer agents, including a bispecific antibody that inhibits both VEGF and Ang2.Visit www.morning
In this podcast, our faculty discuss age-related macular degeneration. What is the disease burden facing these patients, and what are some of the current treatments, particularly for neovascular AMD?Visit www.morningcommutepodcast.com/AMD1 to